Press Room

Press Releases and Statements

Back

Print

DNDi Receives Grant to Develop New Medicines for Neglected Diseases

GENEVA -- The Drugs for Neglected Diseases initiative (DNDi) has received a $25.7 million grant from the Bill & Melinda Gates Foundation to research and develop new medicines to treat human African trypanosomiasis (HAT), also known as sleeping sickness, and visceral leishmaniasis (VL).

"The Bill & Melinda Gates Foundation grant will help DNDi fill critical gaps in the HAT and VL drug development pipelines by supporting our lead optimization drug discovery programs for HAT and VL, which will in turn fuel our drug development projects," stated Dr. Bernard Pecoul, executive director of DNDi. "With the goal of providing better, low-cost treatments, we are intensifying neglected diseases research and are endeavoring to rekindle the hopes of the many people who suffer from these diseases in the poorest regions of the world."

To read the full press release, visit the DNDi Web site.

Visit Our Blog

Connect